In English | En español
Questions About Cancer? 1-800-4-CANCER

Find News Releases

Search For:
Between these dates:

All News Releases

Study of targeted therapies for breast cancer established model for global clinical trials
(Posted: 02/29/2008, Updated: 06/01/2014) - Two targeted medications designed to treat an aggressive form of breast cancer were tested in a study that involved 8,000 participants in 44 countries. While the purpose of this trial was to enable researchers to determine whether dual targeted treatment of early stage HER2-positive breast cancer was better than using a single agent against HER2-positive disease, results of this trial did not show a benefit for women taking the drug combination of trastuzumab or lapatinib. The trial however, did provide a new model for global cancer research and collaboration.
Questions & Answers Play video View the article in Spanish

Clinical trial analysis suggests drug combination may be highly effective in recurrent ovarian cancer
NCI Press Release
(Posted: 05/31/2014) - Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology meeting in Chicago. The trial compared the activity of a combination of the drug olaparib and the blood vessel inhibitor drug cediranib vs. olaparib alone. Trial results showed a near doubling of progression-free survival benefit for the combination therapy over use of the single drug alone.
View the article in Spanish

Treatment helps young women preserve their fertility during breast cancer chemotherapy
NCI Press Release
(Posted: 05/30/2014) - Researchers have found that young women with breast cancer were able to better preserve their fertility during cancer treatments by using hormone-blocking drug injections that put them into temporary menopause. The results announced today at the annual meeting of the American Society of Clinical Oncology in Chicago are from the Prevention of Early Menopause Study (POEMS), a clinical trial sponsored by NCI.
View the article in Spanish

Tiny mutation triggers drug resistance for patients with one type of leukemia
NCI Cancer Center News
(Posted: 05/29/2014) - A multi-institutional team of researchers has pinpointed exactly what goes wrong when chronic lymphocytic leukemia (CLL) patients develop resistance to ibrutinib, a highly effective, precisely targeted anti-cancer drug. In a correspondence published online May 28 in the New England Journal of Medicine, they show how the mutation triggers resistance.

Stanford study could pave way to new treatment for rare jaw tumor
NCI Cancer Center News
(Posted: 05/27/2014) - Researchers have identified the mutations underlying a rare, understudied type of jaw tumor called ameloblastoma, and have also found FDA-approved drugs that may help treat the tumors.

UCSD scientists find gene mutation for aggressive form of pancreatic cancer
NCI Cancer Center News
(Posted: 05/27/2014) - Researchers at the University of California, San Diego School of Medicine have identified a mutated gene common to adenosquamous carcinoma tumors – the first known unique molecular signature for this rare, but particularly virulent, form of pancreatic cancer.

MD Anderson scientists discover potential new target for cancer immunotherapy
NCI Cancer Center News
(Posted: 05/27/2014) - Scientists have found a way to target elusive cells that suppress immune response, depleting them with peptides that spare other important cells and shrink tumors in preclinical experiments.

Albert Einstein College of Medicine study identifies how signals trigger cancer cells to spread
NCI Cancer Center News
(Posted: 05/27/2014) - Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered a signaling pathway in cancer cells that controls their ability to invade nearby tissues in a finely orchestrated manner.

Memorial Sloan-Kettering study suggests double mastectomy often done unnecessarily
NCI Cancer Center News
(Posted: 05/23/2014) - A new study suggests double mastectomies may be performed unnecessarily in many women.

Cold Spring Harbor team validates potential new way to treat HER2-positive breast cancer
NCI Cancer Center News
(Posted: 05/22/2014) - Scientists at Cold Spring Harbor Laboratory today report a discovery that they hope will lead to the development of a powerful new way of treating an aggressive form of breast cancer.

< Previous  6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26  Next >